BRIEF-Syndax Announces Orphan Drug Designation Granted To Axatilimab
BRIEF-Syndax Announces Orphan Drug Designation Granted To Axatilimab
Brief-Syndax宣佈授予Axatilimab孤兒藥物稱號
March 31 (Reuters) - Syndax Pharmaceuticals Inc :
* SYNDAX ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO AXATILIMAB FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* SYNDAX ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO AXATILIMAB FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 31 (Reuters) - Syndax Pharmaceuticals Inc :
* SYNDAX ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO AXATILIMAB FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月31日電-Syndax PharmPharmticals Inc:*Syndax宣佈授予AXATILIMAB孤兒藥物稱號,用於治療慢性移植物抗宿主疾病Eikon的源文本:進一步的公司報道:(Reurs.Briefs@thomsonreurs.com;)
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!